http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
Ionis Pharmaceuticals (IONS) Reports Positive Results from Phase 2 Study of ION224
-
Ionis announces positive results from Phase 2 study of ION224, an investigational medicine demonstrating clinical efficacy in the treatment of NASH/MASH
-
Ionis Pharmaceuticals (IONS) Appoints Kyle Jenne as Chief Global Product Strategy Officer
-
Ionis announces new chief global product strategy officer to lead next phase of commercial growth
-
Ionis to present at upcoming investor conferences
-
Ionis reports fourth quarter and full year 2023 financial results
-
Ionis Pharmaceuticals (IONS) Granted FDA Orphan Drug designation for Olezarsen
-
Olezarsen receives Orphan Drug designation from U.S. FDA for familial chylomicronemia syndrome
-
Ionis Pharmaceuticals (IONS) Granted FDA Fast Track Designation for Eplontersen
-
Eplontersen granted U.S. FDA Fast Track designation for patients with transthyretin-mediated amyloid cardiomyopathy
-
Ionis to hold fourth quarter and full year 2023 financial results webcast
-
Ionis Pharmaceuticals (IONS) Reports Positive Topline Results from Phase 3 OASIS-HAE Study
-
Ionis announces positive topline results from Phase 3 OASIS-HAE study of investigational donidalorsen in patients with hereditary angioedema
-
Praxis Precision Medicines Provides Update on Advancing Clinical Stage Portfolio
-
Ionis poised for continued momentum in 2024 with product launches and key advances in robust pipeline of investigational medicines for serious diseases
-
Ionis Pharmaceuticals (IONS) Announces FDA Approval of WAINUA
-
WAINUA™ (eplontersen) granted regulatory approval in the U.S. for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis
-
Ionis to present at 42nd Annual J.P. Morgan Healthcare Conference
-
Ionis Pharmaceuticals (IONS) announces European licensing agreement with Otsuka for donidalorsen in hereditary angioedema
-
Ionis announces European licensing agreement with Otsuka for donidalorsen in hereditary angioedema
-
Ionis Pharmaceuticals (IONS) Appoints Michael Yang to its Board
-
Ionis announces the appointment of Michael Yang to Board of Directors
-
Praxis Precision Medicines Receives PRIME Designation from the EMA for elsunersen (PRAX-222) for Treatment of SCN2A Gain of Function Developmental Epilepsies
-
Ionis shares positive clinical update from ongoing trial of ION582 for Angelman syndrome
-
Ionis Pharmaceuticals (IONS) Present Positive Two-year Results from Phase 2 Study of donidalorsen
-
Ionis presents positive two-year results from the Phase 2 open label extension study of donidalorsen in patients with hereditary angioedema
-
Ionis to present at upcoming investor conferences
-
Ionis reports third quarter 2023 financial results
-
Ionis to hold third quarter 2023 financial results webcast
-
Ionis shares significant business and pipeline progress at Innovation Day, highlighting strength of capabilities from research and technology through commercialization
-
Praxis Precision Medicines Provides Portfolio Update at 2023 R&D Day
-
Eplontersen Phase 3 results published in JAMA show consistent and sustained benefit
-
Ionis Pharmaceuticals (IONS) enters agreement with Roche for two novel RNA-targeted programs for Alzheimer's disease and Huntington's disease
-
Ionis enters agreement with Roche for two novel RNA-targeted programs for Alzheimer's disease and Huntington's disease
-
Ionis Pharmaceuticals (IONS) Phase 3 study of olezarsen in people with familial chylomicronemia syndrome met its primary endpoint
-
Ionis announces positive olezarsen topline results from Phase 3 study in people with familial chylomicronemia syndrome
-
Ionis to host investor and analyst day event
-
Ionis to present at upcoming investor conferences
-
Ionis reports second quarter 2023 financial results
-
Ionis enters collaboration to advance next generation program targeting Lp(a) for cardiovascular disease
-
Ionis completes enrollment in landmark Phase 3 CARDIO-TTRansform study in patients with TTR-mediated amyloid cardiomyopathy
-
Ionis Pharmaceuticals (IONS) Expands eplontersen Deal with AstraZeneca (AZN) to Include Latin America
-
Ionis expands eplontersen agreement with AstraZeneca to include exclusive rights in Latin America
-
Ionis to hold second quarter 2023 financial results webcast
-
Ionis Pharmaceuticals (IONS) Reports Eplontersen Continued to Show Improvement in ATTRv-PN through 85 weeks
-
Eplontersen continued to show improvement in ATTRv-PN through 85 weeks
-
Ionis to present at upcoming investor conference
-
Biogen (BIIB) Presents New Data on SPINRAZA
-
New data highlight potential benefit of SPINRAZA® (nusinersen) in infants and toddlers with unmet medical needs after gene therapy
-
New Data at Cure SMA Highlight Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs After Gene Therapy
